Zoetis is a global leader in animal health, dedicated to providing innovative products and solutions that enhance the health and well-being of animals. The company develops a broad range of medicines, vaccines, and diagnostic tools for both livestock and companion animals, supporting veterinarians and producers in improving animal health through science-based products. With a commitment to advancing veterinary medicine and sustainability, Zoetis works to ensure safe and sustainable food supply chains while enhancing the quality of life for pets and livestock around the world. Read More
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
The American agricultural sector is facing a formidable challenge in 2025, as a relentless "cost-price squeeze" threatens to significantly erode farm profitability. This economic vise is tightening around producers, caught between stubbornly high input costs for essentials like fertilizer, fuel, and labor, and persistently soft commodity prices for staple crops
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts.
Zoetis’s stock price has taken a beating over the past six months, shedding 28.6% of its value and falling to a new 52-week low of $116.88 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Nashville, TN – November 19, 2025 – Inspire Veterinary Partners, Inc. (NASDAQ: IVP) has been thrust into a precarious financial position, experiencing a staggering -62.27% plummet in its stock value following a non-compliance notice from Nasdaq. The notice, issued on November 13, 2025, concerns the company's failure to meet the minimum
Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic), Senior Vice President of Global Therapeutics. As previously announced, Dr. Esch will succeed Dr. Polzer, effective January 1, 2026. The company will provide updates related to its pipeline, and details about the company’s strategic approach to addressing unmet medical needs for animals, industry-leading R&D capabilities and potential for long-term growth, followed by Q&A.
These cheap dividend stocks would make great cornerstone pieces to any portfolio -- especially for investors looking for a deal in today's somewhat expensive market.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 10.9% gain for healthcare stocks has fallen short of the S&P 500’s 16.4% rise.
Zoetis faced a challenging third quarter, with the market reacting negatively to results that showed flat year-on-year sales and a trim to full-year revenue guidance. Management attributed the muted performance primarily to subdued clinic visits in the U.S. companion animal segment and heightened promotional activity from competitors. CEO Kristin Peck noted, “Growth moderated this quarter driven by a strong year-over-year comp and macro factors, including vet clinic visits and promotional activity.” The company also pointed to social media-driven misperceptions affecting its osteoarthritis pain portfolio, especially Librela, and acknowledged that competitive launches in dermatology created additional headwinds.
As of November 7, 2025, the Pet Products Sector continues to demonstrate remarkable resilience and growth within the S&P 500, buoyed by enduring consumer trends and strategic market alignments. Analysts are observing sustained investor confidence in pet-related enterprises, a testament to the sector's ability to navigate broader economic fluctuations.
The financial markets are once again in the throes of earnings season, a period that consistently proves to be a crucible for individual stock valuations and a significant driver of broader market sentiment. Recent corporate earnings reports, spanning from late 2024 through the third quarter of 2025, have painted a
Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.
Shares of animal health company Zoetis (NYSE:ZTS)
fell 12.6% in the morning session after the company reported mixed third-quarter results and cut its full-year sales forecast. Although its adjusted earnings of $1.70 per share beat Wall Street's estimates, revenue of $2.4 billion was flat year-over-year and met expectations. More concerning for investors, Zoetis lowered its full-year revenue guidance to a midpoint of $9.44 billion, a 0.9% decrease from its previous forecast. The company's operating margin also compressed, falling to 37% from 38.3% in the same quarter last year. Ultimately, the lowered sales outlook and margin pressure overshadowed the earnings beat.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.
Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
